Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Insider: 89Bio, Aprea among week's notable insider trades » 12:40
07/13/20
07/13
12:40
07/13/20
12:40
ETNB

89bio

$33.16 /

+0.78 (+2.41%)

, VCNX

Vaccinex

$4.81 /

+0.86 (+21.77%)

, WTI

W&T Offshore

$2.36 /

+0.055 (+2.39%)

, COO

Cooper Companies

$288.19 /

-1.02 (-0.35%)

, SYNH

Syneos Health

$57.99 /

+1.58 (+2.80%)

, ADPT

Adaptive Biotechnologies

$47.00 /

+1.04 (+2.26%)

, ALNY

Alnylam

$161.08 /

-1.25 (-0.77%)

, BILL

Bill.com

$90.35 /

+0.66 (+0.74%)

, CIEN

Ciena

$54.81 /

-0.17 (-0.31%)

, APRE

Aprea Therapeutics

$29.35 /

-0.12 (-0.41%)

Welcome to "Fly Insider,"…

Open Full Text

ShowHide Related Items >><<
WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

ETNB 89bio
$33.16 /

+0.78 (+2.41%)

COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

APRE Aprea Therapeutics
$29.35 /

-0.12 (-0.41%)

ALNY Alnylam
$161.08 /

-1.25 (-0.77%)

ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

ETNB 89bio
$33.16 /

+0.78 (+2.41%)

07/07/20 Chardan
89bio initiated with a Buy at Chardan
12/09/19 Oppenheimer
89bio initiated with an Outperform at Oppenheimer
12/09/19 SVB Leerink
89bio initiated with an Outperform at SVB Leerink
12/09/19 RBC Capital
89bio initiated with an Outperform at RBC Capital
VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

04/17/20 Roth Capital
W&T Offshore upgraded to Buy from Neutral at Roth Capital
03/13/20 Roth Capital
W&T Offshore downgraded to Neutral from Buy at Roth Capital
03/09/20 Stifel
W&T Offshore downgraded to Hold from Buy at Stifel
COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/06/20 Baird
Cooper Companies downgraded to Neutral from Outperform at Baird
06/05/20 UBS
UBS backs Buy on Alcon after Cooper results
05/26/20 Stephens
Cooper Companies price target raised to $325 from $300 at Stephens
SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

04/03/20 Mizuho
Syneos Health price target lowered to $42 from $56 at Mizuho
04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
ALNY Alnylam
$161.08 /

-1.25 (-0.77%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BILL Bill.com
$90.35 /

+0.66 (+0.74%)

06/29/20 Goldman Sachs
Bill.com price target raised to $90 from $60 at Goldman Sachs
05/28/20
Fly Intel: Top five analyst upgrades
05/28/20 Piper Sandler
Bill.com upgraded to Overweight from Neutral at Piper Sandler
05/18/20 KeyBanc
Bill.com price target raised to $85 from $76 at KeyBanc
CIEN Ciena
$54.81 /

-0.17 (-0.31%)

06/05/20 JPMorgan
JPMorgan ups Ciena target to $63 from $53, adds to Analyst Focus List
06/05/20 Stifel
Ciena price target raised to $61 from $54 at Stifel
06/05/20 Cowen
Ciena price target raised to $73 from $69 at Cowen
06/05/20 Barclays
Ciena price target raised to $67 from $48 at Barclays
APRE Aprea Therapeutics
$29.35 /

-0.12 (-0.41%)

06/22/20
Fly Intel: Top five analyst initiations
06/22/20 H.C. Wainwright
Aprea Therapeutics initiated with a Neutral at H.C. Wainwright
04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

ETNB 89bio
$33.16 /

+0.78 (+2.41%)

COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

APRE Aprea Therapeutics
$29.35 /

-0.12 (-0.41%)

ALNY Alnylam
$161.08 /

-1.25 (-0.77%)

ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

  • 08
    Jul
  • 11
    Jun
  • 24
    Jan
  • 12
    Dec
  • 11
    Nov
  • 03
    Oct
SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

ETNB 89bio
$33.16 /

+0.78 (+2.41%)

COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

Over a week ago
Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 05:55
06/24/20
06/24
05:55
06/24/20
05:55
A

Agilent

$89.36 /

+0.81 (+0.91%)

, ABBV

AbbVie

$97.28 /

+0.03 (+0.03%)

, ADPT

Adaptive Biotechnologies

$46.95 /

+1.04 (+2.27%)

, AZN

AstraZeneca

$54.24 /

+0.8 (+1.50%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$187.74 /

+4.42 (+2.41%)

, BMY

Bristol-Myers

$58.41 /

+0.85 (+1.48%)

, BNTX

BioNTech

$52.80 /

-4.64 (-8.08%)

, CRL

Charles River

$175.05 /

-0.12 (-0.07%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$83.33 /

+0.26 (+0.31%)

, GILD

Gilead

$75.01 /

-0.61 (-0.81%)

, PFE

Pfizer

$32.78 /

-0.33 (-1.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVCR

Novocure

$62.71 /

-0.31 (-0.49%)

, NTRA

Natera

$46.65 /

+0.36 (+0.78%)

, SNY

Sanofi

$52.49 /

-0.06 (-0.11%)

, RUBY

Rubius Therapeutics

$6.52 /

-0.02 (-0.31%)

, NEO

NeoGenomics

$29.05 /

+0.49 (+1.72%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$25.06 /

-0.75 (-2.91%)

, QGEN

Qiagen

$42.87 /

+0.31 (+0.73%)

, LLY

Eli Lilly

$159.35 /

-1.06 (-0.66%)

, PKI

PerkinElmer

$99.11 /

+1.08 (+1.10%)

, GSK

GlaxoSmithKline

$41.60 /

+0.37 (+0.90%)

, ILMN

Illumina

$367.22 /

+7.02 (+1.95%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

NTRA Natera
$46.65 /

+0.36 (+0.78%)

NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$175.05 /

-0.12 (-0.07%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

A Agilent
$89.36 /

+0.81 (+0.91%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

06/23/20
Fly Intel: Top five analyst upgrades
06/23/20 Atlantic Equities
AbbVie upgraded to Overweight from Neutral at Atlantic Equities
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/23/20 Berenberg
Bayer price target raised to EUR 86 from EUR 82 at Berenberg
06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$175.05 /

-0.12 (-0.07%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$83.33 /

+0.26 (+0.31%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$75.01 /

-0.61 (-0.81%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$32.78 /

-0.33 (-1.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$62.71 /

-0.31 (-0.49%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.65 /

+0.36 (+0.78%)

06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
06/23/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
ILMN Illumina
$367.22 /

+7.02 (+1.95%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

NTRA Natera
$46.65 /

+0.36 (+0.78%)

NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

CRL Charles River
$175.05 /

-0.12 (-0.07%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 04:55
06/23/20
06/23
04:55
06/23/20
04:55
A

Agilent

$88.55 /

-0.27 (-0.30%)

, ABBV

AbbVie

$97.25 /

+0.53 (+0.55%)

, ADPT

Adaptive Biotechnologies

$45.91 /

+1.24 (+2.78%)

, AZN

AstraZeneca

$53.44 /

+0.39 (+0.74%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$183.32 /

+0.75 (+0.41%)

, BMY

Bristol-Myers

$57.56 /

+1.22 (+2.17%)

, BNTX

BioNTech

$57.44 /

+6.02 (+11.71%)

, CRL

Charles River

$175.17 /

-3.21 (-1.80%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$83.07 /

+4.14 (+5.25%)

, GILD

Gilead

$75.62 /

-1.61 (-2.08%)

, PFE

Pfizer

$33.11 /

-0.32 (-0.96%)

, NVS

Novartis

$90.58 /

-0.55 (-0.60%)

, NVCR

Novocure

$63.02 /

-0.33 (-0.52%)

, NTRA

Natera

$46.29 /

-0.16 (-0.34%)

, SNY

Sanofi

$52.55 /

+0.25 (+0.48%)

, RUBY

Rubius Therapeutics

$6.54 /

+0.07 (+1.08%)

, NEO

NeoGenomics

$28.56 /

+0.17 (+0.60%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$25.81 /

-0.23 (-0.88%)

, QGEN

Qiagen

$42.56 /

-0.03 (-0.07%)

, LLY

Eli Lilly

$160.41 /

+0.51 (+0.32%)

, PKI

PerkinElmer

$98.03 /

-0.48 (-0.49%)

, GSK

GlaxoSmithKline

$41.23 /

+0.11 (+0.27%)

, ILMN

Illumina

$360.20 /

-10.23 (-2.76%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

NTRA Natera
$46.29 /

-0.16 (-0.34%)

NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$175.17 /

-3.21 (-1.80%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

A Agilent
$88.55 /

-0.27 (-0.30%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
06/04/20 BMO Capital
Dicamba ruling likely a mid-term positive for Corteva, says BMO Capital
BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$175.17 /

-3.21 (-1.80%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$83.07 /

+4.14 (+5.25%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$75.62 /

-1.61 (-2.08%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$33.11 /

-0.32 (-0.96%)

06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
06/16/20 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
NVS Novartis
$90.58 /

-0.55 (-0.60%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$63.02 /

-0.33 (-0.52%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.29 /

-0.16 (-0.34%)

06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
06/09/20 Morgan Stanley
Sanofi price target raised to EUR 107 from EUR 101 at Morgan Stanley
RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
06/16/20 Guggenheim
Eli Lilly upgraded to Buy from Neutral at Guggenheim
PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
ILMN Illumina
$360.20 /

-10.23 (-2.76%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

NTRA Natera
$46.29 /

-0.16 (-0.34%)

NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

CRL Charles River
$175.17 /

-3.21 (-1.80%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 08:42
06/22/20
06/22
08:42
06/22/20
08:42
A

Agilent

$88.82 /

+0.6 (+0.68%)

, ABBV

AbbVie

$96.72 /

+0.45 (+0.47%)

, ADPT

Adaptive Biotechnologies

$44.67 /

+0.14 (+0.31%)

, AZN

AstraZeneca

$53.05 /

+0.39 (+0.74%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$182.57 /

+5.09 (+2.87%)

, BMY

Bristol-Myers

$56.34 /

+0.35 (+0.63%)

, BNTX

BioNTech

$51.42 /

+0.48 (+0.94%)

, CRL

Charles River

$178.38 /

-0.31 (-0.17%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$78.93 /

-0.62 (-0.78%)

, GILD

Gilead

$77.23 /

+3.18 (+4.29%)

, PFE

Pfizer

$33.43 /

+0.2 (+0.60%)

, NVS

Novartis

$91.13 /

+1.47 (+1.64%)

, NVCR

Novocure

$63.35 /

+0.83 (+1.33%)

, NTRA

Natera

$46.45 /

+0.43 (+0.93%)

, SNY

Sanofi

$52.30 /

+0.84 (+1.63%)

, RUBY

Rubius Therapeutics

$6.47 /

+0.09 (+1.41%)

, NEO

NeoGenomics

$28.39 /

+0.145 (+0.51%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$26.04 /

-1.46 (-5.31%)

, QGEN

Qiagen

$42.59 /

+0.17 (+0.40%)

, LLY

Eli Lilly

$159.90 /

-1.14 (-0.71%)

, PKI

PerkinElmer

$98.51 /

+0.565 (+0.58%)

, GSK

GlaxoSmithKline

$41.12 /

+0.18 (+0.44%)

, ILMN

Illumina

$370.43 /

+8.18 (+2.26%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

NTRA Natera
$46.45 /

+0.43 (+0.93%)

NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$178.38 /

-0.31 (-0.17%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

A Agilent
$88.82 /

+0.6 (+0.68%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
06/04/20 BMO Capital
Dicamba ruling likely a mid-term positive for Corteva, says BMO Capital
BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$178.38 /

-0.31 (-0.17%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$78.93 /

-0.62 (-0.78%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$77.23 /

+3.18 (+4.29%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$33.43 /

+0.2 (+0.60%)

06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
06/16/20 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
06/08/20 Piper Sandler
Opko Health, Pfizer data show IGF-1 normal at ENDO, says Piper Sandler
NVS Novartis
$91.13 /

+1.47 (+1.64%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$63.35 /

+0.83 (+1.33%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.45 /

+0.43 (+0.93%)

06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
05/07/20 JPMorgan
Natera upgraded to Overweight from Neutral at JPMorgan
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
06/09/20 Morgan Stanley
Sanofi price target raised to EUR 107 from EUR 101 at Morgan Stanley
RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
06/16/20 Guggenheim
Eli Lilly upgraded to Buy from Neutral at Guggenheim
PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
ILMN Illumina
$370.43 /

+8.18 (+2.26%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

NTRA Natera
$46.45 /

+0.43 (+0.93%)

NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

CRL Charles River
$178.38 /

-0.31 (-0.17%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

Recommendations
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim » 08:09
06/18/20
06/18
08:09
06/18/20
08:09
ADPT

Adaptive Biotechnologies

$44.17 /

+0.52 (+1.19%)

After surveying 42…

After surveying 42 oncologists, including fifteen hematological oncologists, Guggenheim analyst David Westenberg said the survey results confirm the potential for strong adoption of minimal residual disease, or MRD, testing. He believes the survey suggests there are strong tailwinds driving increases in MRD and that Adaptive Biotechnologies will benefit given "its best in class MRD testing option," the analyst tells investors. Westenberg reiterates a Buy rating and $50 price target on Adaptive shares.

ShowHide Related Items >><<
ADPT Adaptive Biotechnologies
$44.17 /

+0.52 (+1.19%)

ADPT Adaptive Biotechnologies
$44.17 /

+0.52 (+1.19%)

06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
05/13/20 JPMorgan
Adaptive reported 'healthy' Q1 results, says JPMorgan
ADPT Adaptive Biotechnologies
$44.17 /

+0.52 (+1.19%)

ADPT Adaptive Biotechnologies
$44.17 /

+0.52 (+1.19%)

Over a month ago
Initiation
Fly Intel: Top five analyst initiations » 10:08
06/03/20
06/03
10:08
06/03/20
10:08
ADPT

Adaptive Biotechnologies

$40.80 /

+2.15 (+5.56%)

, DECK

Deckers Brands

$208.43 /

+4.43 (+2.17%)

, ALLE

Allegion

$102.69 /

+2.685 (+2.68%)

, WMG

Warner Music

$0.00 /

+ (+0.00%)

, EXP

Eagle Materials

$71.82 /

+2.22 (+3.19%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adaptive Biotechnologies (ADPT) initiated with a Buy at Goldman Sachs. 2. Deckers Brands (DECK) initiated with an Outperform at Cowen. 3. Allegion (ALLE) initiated with a Market Perform at William Blair. 4. Warner Music (WMG) initiated with a Neutral at Atlantic Equities. 5. Eagle Materials (EXP) reinstated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
WMG Warner Music
$0.00 /

+ (+0.00%)

EXP Eagle Materials
$71.82 /

+2.22 (+3.19%)

DECK Deckers Brands
$208.43 /

+4.43 (+2.17%)

ALLE Allegion
$102.69 /

+2.685 (+2.68%)

ADPT Adaptive Biotechnologies
$40.80 /

+2.15 (+5.56%)

ADPT Adaptive Biotechnologies
$40.80 /

+2.15 (+5.56%)

06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
05/13/20 JPMorgan
Adaptive reported 'healthy' Q1 results, says JPMorgan
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
DECK Deckers Brands
$208.43 /

+4.43 (+2.17%)

06/03/20 Cowen
Cowen likes its brand durability, initiated Deckers Brands with Outperform
06/03/20 Cowen
Deckers Brands initiated with an Outperform at Cowen
05/22/20 BTIG
Deckers Brands price target raised to $208 from $201 at BTIG
05/22/20 Susquehanna
Deckers Brands price target raised to $200 from $175 at Susquehanna
ALLE Allegion
$102.69 /

+2.685 (+2.68%)

06/03/20 William Blair
William Blair starts Allegion at Market Perform due to valuation
06/03/20 William Blair
Allegion initiated with a Market Perform at William Blair
05/21/20 Barclays
Allegion downgraded to Underweight from Equal Weight at Barclays
04/27/20 Imperial Capital
Allegion price target lowered to $100 from $120 at Imperial Capital
WMG Warner Music
$0.00 /

+ (+0.00%)

06/03/20 Atlantic Equities
Warner Music initiated with a Neutral at Atlantic Equities
EXP Eagle Materials
$71.82 /

+2.22 (+3.19%)

06/03/20 Goldman Sachs
Eagle Materials reinstated with a Neutral at Goldman Sachs
05/22/20 JPMorgan
JPMorgan upgrades Martin Marietta with 17% upside into year-end
05/20/20 Raymond James
Eagle Materials upgraded to Outperform from Market Perform at Raymond James
05/20/20 Raymond James
Eagle Materials upgraded to Outperform from Market Perform at Raymond James
EXP Eagle Materials
$71.82 /

+2.22 (+3.19%)

DECK Deckers Brands
$208.43 /

+4.43 (+2.17%)

ALLE Allegion
$102.69 /

+2.685 (+2.68%)

ADPT Adaptive Biotechnologies
$40.80 /

+2.15 (+5.56%)

  • 03
    Jun
WMG Warner Music
$0.00 /

+ (+0.00%)

EXP Eagle Materials
$71.82 /

+2.22 (+3.19%)

WMG Warner Music
$0.00 /

+ (+0.00%)

EXP Eagle Materials
$71.82 /

+2.22 (+3.19%)

DECK Deckers Brands
$208.43 /

+4.43 (+2.17%)

ADPT Adaptive Biotechnologies
$40.80 /

+2.15 (+5.56%)

Initiation
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs » 05:03
06/03/20
06/03
05:03
06/03/20
05:03
ADPT

Adaptive Biotechnologies

$38.65 /

-0.43 (-1.10%)

, MSFT

Microsoft

$184.95 /

+2.09 (+1.14%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $60 price target. The launch of the Microsoft-partnered immunoSEQ Dx in 2021, a clinical diagnostic incorporating machine learning to match immune responses to disease states, and Adaptive's drug discovery pipeline, including a cell therapy collaboration in oncology with Genentech and future sole expansion into autoimmune disease alongside cancer vaccines, provide "two key growth levers," Richter tells investors in a research note. The analyst is positive on the company's "innovative technology platform and future trajectory of the business model."

ShowHide Related Items >><<
MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

ADPT Adaptive Biotechnologies
$38.65 /

-0.43 (-1.10%)

ADPT Adaptive Biotechnologies
$38.65 /

-0.43 (-1.10%)

05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
05/13/20 JPMorgan
Adaptive reported 'healthy' Q1 results, says JPMorgan
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

06/02/20 Wells Fargo
Microsoft price target raised to $250 from $205 at Wells Fargo
06/02/20 Cowen
Cowen starts Slack with Outperform given 'major booster shot' from COVID
05/28/20 Needham
Workday price target raised to $200 from $175 at Needham
05/27/20 Summit Insights
Microsoft initiated with a Buy at Summit Insights
MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

ADPT Adaptive Biotechnologies
$38.65 /

-0.43 (-1.10%)

MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

ADPT Adaptive Biotechnologies
$38.65 /

-0.43 (-1.10%)

MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

Recommendations
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim » 08:48
05/19/20
05/19
08:48
05/19/20
08:48
ADPT

Adaptive Biotechnologies

$39.30 /

+1.23 (+3.23%)

Guggenheim analyst David…

Guggenheim analyst David Westenberg raised the firm's price target on Adaptive Biotechnologies to $50 from $44, stating that he thinks investors underestimate the platform validation impact of a COVID-19 test for the company. He contends that "a COVID-19 preoccupied health care system might facilitate the adoption of a paradigm-changing technology, more so than in a non-COVID environment," while adding that COVID-19 "fits perfectly into Adaptive's existing R&D efforts." Westenberg keeps a Buy rating on Adaptive shares.

ShowHide Related Items >><<
ADPT Adaptive Biotechnologies
$39.30 /

+1.23 (+3.23%)

ADPT Adaptive Biotechnologies
$39.30 /

+1.23 (+3.23%)

05/13/20 JPMorgan
Adaptive reported 'healthy' Q1 results, says JPMorgan
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
11/13/19 JPMorgan
Adaptive Biotechnologies still has upside potential despite rally, says JPMorgan
ADPT Adaptive Biotechnologies
$39.30 /

+1.23 (+3.23%)

ADPT Adaptive Biotechnologies
$39.30 /

+1.23 (+3.23%)

Recommendations
Adaptive reported 'healthy' Q1 results, says JPMorgan » 09:15
05/13/20
05/13
09:15
05/13/20
09:15
ADPT

Adaptive Biotechnologies

$38.10 /

-0.03 (-0.08%)

, LH

LabCorp

$163.75 /

-5.48 (-3.24%)

JPMorgan analyst Tycho…

JPMorgan analyst Tycho Peterson views Adaptive Biotechnologies' Q1 results as "healthy" and believes the company's pipeline remains on track despite some COVID-19 disruption. While Adaptive saw a 30% drop in clinical volumes in late March versus the first eight weeks of the quarter as people began to avoid non-essential hospital visits, it saw an improvement in order trends in the first two weeks of May, with the partnership with LabCorp (LH) set to further enable remote blood collection going forward, Peterson tells investors in a research note. The analyst continues to view Adaptive as being "uniquely positioned" in immune-based diagnostics and therapeutics, with a "meaningful call option" around drug discovery milestones and royalties. He keeps an Overweight rating on the shares with a $45 price target.

ShowHide Related Items >><<
LH LabCorp
$163.75 /

-5.48 (-3.24%)

ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
11/13/19 JPMorgan
Adaptive Biotechnologies still has upside potential despite rally, says JPMorgan
07/23/19
Fly Intel: Top five analyst initiations
LH LabCorp
$163.75 /

-5.48 (-3.24%)

04/30/20 JPMorgan
LabCorp price target raised to $188 from $149 at JPMorgan
04/29/20 KeyBanc
LabCorp downgraded at KeyBanc after sharp recovery in share price
04/29/20 KeyBanc
LabCorp downgraded to Sector Weight from Overweight at KeyBanc
04/27/20
Fly Intel: Top five analyst upgrades
LH LabCorp
$163.75 /

-5.48 (-3.24%)

ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

LH LabCorp
$163.75 /

-5.48 (-3.24%)

ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

LH LabCorp
$163.75 /

-5.48 (-3.24%)

On The Fly
Fly Intel: Pre-market Movers » 09:11
05/13/20
05/13
09:11
05/13/20
09:11
GILD

Gilead

$77.94 /

-2.86 (-3.54%)

, ROKU

Roku

$127.14 /

-5.06 (-3.83%)

, JCP

J.C. Penney

$0.20 /

+0.0447 (+29.06%)

, JD

JD.com

$47.03 /

+0.31 (+0.66%)

, LVS

Las Vegas Sands

$45.97 /

-2.51 (-5.18%)

, MYL

Mylan

$16.21 /

-0.7 (-4.14%)

, UNFI

United Natural Foods

$15.54 /

+2.87 (+22.65%)

, CYBR

CyberArk

$109.65 /

-5.33 (-4.64%)

, INFN

Infinera

$5.81 /

+0.17 (+3.01%)

, ADPT

Adaptive Biotechnologies

$38.10 /

-0.03 (-0.08%)

, NE

Noble Corp.

$0.21 /

+0.0035 (+1.74%)

, BLUE

Bluebird Bio

$56.85 /

-3.37 (-5.60%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

ROKU Roku
$127.14 /

-5.06 (-3.83%)

NE Noble Corp.
$0.21 /

+0.0035 (+1.74%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

JD JD.com
$47.03 /

+0.31 (+0.66%)

JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

INFN Infinera
$5.81 /

+0.17 (+3.01%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

CYBR CyberArk
$109.65 /

-5.33 (-4.64%)

BLUE Bluebird Bio
$56.85 /

-3.37 (-5.60%)

ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

05/11/20 RBC Capital
Gilead's U.S. remdesivir supply to be 'severely constrained', says RBC Capital
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Citi
ICER value of Remdesivir at $4,500 supportive of value, says Citi
05/04/20 Benchmark
Regeneron report more about COVID-19 progress than earnings, says Benchmark
ROKU Roku
$127.14 /

-5.06 (-3.83%)

05/08/20 Susquehanna
Roku price target lowered to $145 from $170 at Susquehanna
05/08/20 Loop Capital
Roku price target raised to $90 from $70 at Loop Capital
05/08/20 Wedbush
Roku price target raised to $136 from $86 at Wedbush
04/29/20
Fly Intel: Top five analyst initiations
JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

04/16/20 Oppenheimer
Ulta Beauty price target raised to $240 from $220 at Oppenheimer
01/14/20 Oppenheimer
Ulta Beauty price target raised to $310 from $275 at Oppenheimer
11/18/19 Deutsche Bank
Deutsche Bank stays on sidelines despite J.C. Penney's margin gains
07/25/19 Oppenheimer
Ulta Beauty price target raised to $390 from $370 at Oppenheimer
JD JD.com
$47.03 /

+0.31 (+0.66%)

05/13/20 Mizuho
JD.com upgraded to Buy from Neutral at Mizuho
04/14/20 Morgan Stanley
JD.com upgraded to Overweight from Equal Weight at Morgan Stanley
03/17/20 Bernstein
JD.com upgraded to Outperform from Market Perform at Bernstein
03/03/20 Susquehanna
JD.com price target raised to $45 from $35 at Susquehanna
LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

05/06/20 Roth Capital
Las Vegas Sands price target lowered to $52 from $69 at Roth Capital
04/23/20
Fly Intel: Top five analyst upgrades
04/23/20 JPMorgan
JPMorgan upgrades Las Vegas Sands to Overweight, sees entry point
04/23/20 Deutsche Bank
Las Vegas Sands price target raised to $54 from $50 at Deutsche Bank
MYL Mylan
$16.21 /

-0.7 (-4.14%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

05/13/20 Wells Fargo
United Natural Foods upgraded to Equal Weight on COVID benefits at Wells Fargo
05/13/20 Wells Fargo
United Natural Foods upgraded to Equal Weight from Underweight at Wells Fargo
03/19/20 Barclays
United Natural Foods upgraded to Equal Weight from Underweight at Barclays
03/18/20 BMO Capital
United Natural Foods upgraded to Market Perform from Underperform at BMO Capital
CYBR CyberArk
$109.65 /

-5.33 (-4.64%)

04/08/20 DA Davidson
DA Davidson says Proofpoint, SailPoint have strongest pipelines in sector
03/24/20 Goldman Sachs
Goldman Sachs starts Rapid7, Tenable Holdings at Buy, SailPoint at Sell
03/24/20 Goldman Sachs
CyberArk initiated with a Neutral at Goldman Sachs
03/23/20 Piper Sandler
CyberArk upgraded to Overweight on recent selloff at Piper Sandler
INFN Infinera
$5.81 /

+0.17 (+3.01%)

05/13/20 Northland
Infinera downgraded to Market Perform with $5 target at Northland
05/13/20 Northland
Infinera downgraded to Market Perform from Outperform at Northland
05/13/20 MKM Partners
Infinera price target lowered to $7.50 from $10.50 at MKM Partners
05/13/20 Northland
Infinera downgraded to Market Perform from Outperform at Northland
ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
11/13/19 JPMorgan
Adaptive Biotechnologies still has upside potential despite rally, says JPMorgan
07/23/19
Fly Intel: Top five analyst initiations
NE Noble Corp.
$0.21 /

+0.0035 (+1.74%)

05/13/20 Credit Suisse
Noble Corp. downgraded to Underperform from Neutral at Credit Suisse
04/21/20 RBC Capital
Noble Corp. downgraded to Underperform from Sector Perform at RBC Capital
03/17/20 Capital One
Noble Corp. downgraded to Underweight from Equalweight at Capital One
03/13/20 Wells Fargo
Drillers downgraded at Wells Fargo on recent sell off in commodity prices
BLUE Bluebird Bio
$56.85 /

-3.37 (-5.60%)

05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
05/11/20 Piper Sandler
Bluebird Bio price target lowered to $70 from $75 at Piper Sandler
03/27/20 BMO Capital
Bluebird Bio price target lowered to $107 from $132 at BMO Capital
UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

ROKU Roku
$127.14 /

-5.06 (-3.83%)

NE Noble Corp.
$0.21 /

+0.0035 (+1.74%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

JD JD.com
$47.03 /

+0.31 (+0.66%)

JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

INFN Infinera
$5.81 /

+0.17 (+3.01%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

CYBR CyberArk
$109.65 /

-5.33 (-4.64%)

BLUE Bluebird Bio
$56.85 /

-3.37 (-5.60%)

ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

ROKU Roku
$127.14 /

-5.06 (-3.83%)

NE Noble Corp.
$0.21 /

+0.0035 (+1.74%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

JD JD.com
$47.03 /

+0.31 (+0.66%)

JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

ROKU Roku
$127.14 /

-5.06 (-3.83%)

NE Noble Corp.
$0.21 /

+0.0035 (+1.74%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

JD JD.com
$47.03 /

+0.31 (+0.66%)

JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

CYBR CyberArk
$109.65 /

-5.33 (-4.64%)

UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

ROKU Roku
$127.14 /

-5.06 (-3.83%)

MYL Mylan
$16.21 /

-0.7 (-4.14%)

LVS Las Vegas Sands
$45.97 /

-2.51 (-5.18%)

JD JD.com
$47.03 /

+0.31 (+0.66%)

JCP J.C. Penney
$0.20 /

+0.0447 (+29.06%)

INFN Infinera
$5.81 /

+0.17 (+3.01%)

GILD Gilead
$77.94 /

-2.86 (-3.54%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.